Acute Monoblastic Leukemia (AmoL)Symptoms, Doctors, Treatments, Advances & More
Learn About Acute Monoblastic Leukemia (AmoL)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Montefiore Medical Center
Marina Konopleva, MD, Phd, is Professor, Oncology, Professor, Molecular Pharmacology, Director, Leukemia Program and Co-Director, Blood Cancer Institute, at Montefiore Einstein. Her clinic focus centers on treating patients with hematologic malignancies, with an emphasis on acute myeloid and acute lymphoblastic leukemia. She has additional expertise in treating patients with high-risk myelodysplastic syndrome and chronic myeloid leukemia. Dr. Konopleva is rated as an Elite provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). She is also highly rated in 25 other conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.
University Of Colorado Hospital
Daniel Pollyea is a Hematologist practicing medicine in Aurora, Colorado. Dr. Pollyea is rated as an Elite provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Monoblastic Leukemia (AmoL), Bone Marrow Aspiration, and Bone Marrow Transplant.
Bo Lei practices practicing medicine in Zhengzhou, China. Mr. Lei is rated as an Elite expert by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Acute Monoblastic Leukemia (AmoL), Cone-Rod Dystrophy, X-Linked Juvenile Retinoschisis, Vitrectomy, and Cataract Removal.
Summary: This phase II trial tests how well venetoclax with cladribine and cytarabine alternating with azacitidine and venetoclax works in treating patients with newly diagnosed monocytic acute myeloid leukemia (AML) and active signaling mutated AML. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein neede...
Summary: This study is a multicenter, randomized, prospective Phase II clinical trial designed to compare the effectiveness of two treatment approaches for patients with acute monocytic leukemia.